This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surpasses both earnings and sales estimates in the third quarter of 2018.
Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.
Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
by Zacks Equity Research
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.
Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR
by Ryan McQueeney
Ryan McQueeney chats with Dave Bartosiak about the near-term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report. The host also recaps earnings results from CVS, Eli Lilly, and Regeneron.
September JOLTS Report In Spotlight
by Zacks Equity Research
September JOLTS Report In Spotlight
Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings
by Mark Vickery
We won't get the final numbers until later, so until then we're just playing the waiting game.
Lilly (LLY) Tops Q3 Earnings, Lifts 2018 Outlook, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for earnings but misses the same for sales. The company raises its previously issued outlook for adjusted earnings. Stock rises in pre-market trading.
Eli Lilly (LLY) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 1.46% and -0.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.
Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview
by Zacks Equity Research
Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview
Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3
by Zacks Equity Research
Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.
AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
by Zacks Equity Research
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss
by Zacks Equity Research
Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise
by Zacks Equity Research
Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
by Zacks Equity Research
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Earnings Estimates Coming Down
by Sheraz Mian
Some areas of weakness have emerged, with companies struggling to beat revenue estimates and a number of leading companies providing underwhelming guidance.
Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $108.98, moving +0.59% from the previous trading session.
Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Sanofi (SNY) beats on earnings as well as sales in the third quarter of 2018. Sales benefit from the performance of Specialty care segment and recovery in Vaccine segment.
The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead
by Kinjel Shah
Pipeline success, cost cutting, share buybacks, product launches, increased M&A and collaboration activities are the factors that drives the large-cap pharma industry.